RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months ended December 31, 2016
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets prescription and over-the-counter finished pharmaceutical products, active pharmaceutical ingredients (APIs), and custom pharmaceutical services globally.

Key Financial Metrics

All figures in Indian Rupees (Rs.) in millions, unless otherwise noted. Convenience translation to U.S. dollars provided where available in the filing.

Income Statement Highlights (Nine Months Ended Dec 31, 2016)

Balance Sheet Highlights (As of Dec 31, 2016)

Cash Flow Highlights (Nine Months Ended Dec 31, 2016)

• Net Cash from Operating Activities: Rs. 12,996 million (U.S.$192 million), a decrease from Rs. 31,991 million in the prior year.
• Net Cash Used in Investing Activities: Rs. (15,231) million (U.S.$225 million), driven by acquisitions of intangible assets and property, plant, and equipment.
• Net Cash from Financing Activities: Rs. 3,704 million (U.S.$55 million), primarily due to short-term borrowings offset by share buybacks and dividend payments.

Material Changes vs. Prior Period

• Revenue Decline: Consolidated revenues decreased 10% year-over-year (YoY) for the nine months ended Dec 31, 2016. The Global Generics segment, which accounts for the majority of revenue, declined 11% due to price erosion in North America, volume decreases, and a voluntary reduction of supply to Venezuela.
• Profitability Compression: Net profit dropped 54% YoY. Operating margins contracted significantly due to increased competition, lower realizations on key molecules, and higher R&D and SG&A expenses.
• Debt Profile Shift: Short-term borrowings increased significantly (from Rs. 22,718 million to Rs. 52,158 million) primarily to fund the acquisition of eight Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceutical Industries Limited. Long-term borrowings decreased due to repayments and refinancing.
• Share Buyback: The company completed a buyback of 5,077,504 equity shares for an aggregate price of Rs. 15,694 million during the period.
• Acquisitions: Significant capital was deployed to acquire intangible assets, including ANDAs from Teva (Rs. 23,366 million), rights to a new chemical entity from XenoPort (Rs. 3,159 million), and OTC brands from Ducere Pharma (Rs. 1,148 million).

Guidance, Outlook, Risks, and Contingencies

Management Commentary and Outlook

Management attributes the revenue decline to intense competition in the North American generics market and the strategic decision to mitigate risk by reducing supply to Venezuela amidst its economic crisis. The company continues to invest in R&D for complex formulations and biosimilars. The acquisition of the Teva ANDAs is expected to strengthen the Global Generics portfolio in the U.S.

Key Risks and Contingencies

• Regulatory Actions (U.S. FDA): The company received a warning letter in November 2015 regarding cGMP deviations at three manufacturing facilities in India (Srikakulam, Miryalaguda, and Duvvada). Re-inspection is scheduled for early 2017. Failure to resolve these issues could result in import bans or withholding of new product approvals.
• Venezuela Operations: Ongoing economic crisis and currency devaluation in Venezuela have severely impacted revenues from this region. The company has recognized significant foreign exchange losses and inventory write-downs related to these operations.
• Legal and Litigation:
  • Antitrust Litigation: The company is involved in class action lawsuits in the U.S. regarding alleged antitrust violations related to patent settlements for Nexium and Namenda. The company believes liability is not probable.
  • Pricing Litigation: Investigations and lawsuits regarding pricing and price reporting practices are ongoing in Pennsylvania and other jurisdictions.
  • Indian Regulatory (NPPA): Disputes with the National Pharmaceutical Pricing Authority regarding price controls on Norfloxacin and cardiovascular/anti-diabetic formulations. Provisions have been recorded for potential liabilities.
• Environmental Matters: Pending litigation regarding land and water pollution in India, though the company believes additional liability is remote.

Investor Verification Checklist

• U.S. FDA Compliance Status: Verify the outcome of the scheduled re-inspections of Indian manufacturing facilities in early 2017 and any subsequent regulatory actions.
• Venezuela Exposure: Monitor the company's ability to repatriate funds and the extent of further revenue erosion or asset impairment in Venezuela.
• ANDA Integration: Assess the timeline for commercialization of the eight ANDAs acquired from Teva and their contribution to future revenue growth.
• North American Market Share: Track market share trends for key molecules in the U.S. to gauge the impact of price erosion and competition.
• Debt Servicing: Review the interest rate profile of the increased short-term borrowings and the company's ability to service this debt given the decline in operating cash flow.
• Legal Provisions: Monitor developments in the NPPA pricing disputes and U.S. antitrust litigation to ensure provisions remain adequate.